← SynDRA
MK-5108
SynDRA canonical compound SYN0038334 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | AURKB |
|---|
| Mechanism of action | Aurora kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- aurora kinase inhibitor
- AURKA INHIBITOR
- Serine/threonine-protein kinase Aurora-A inhibitor
- AURKB INHIBITOR
- AURKC INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- AAK1
- PGRMC1
- PDXK
- PDGFRB
- PCYT1A
- PASK
- PAK6
- PAK4
- PAK2
- PAICS
- OPA1
- OLA1
- NUAK2
- NTRK1
- NQO2
- NLK
- NEK9
- PFKP
- PHKG2
- NEK3
- PIM1
- PRKCA
- PRKAR2A
- PRKAG2
- PRKAG1
- PRKACB
- PRKACA
- PRKAA1
- PLK4
- PKN3
- PKN2
- PKN1
- PKMYT1
- PIP4K2C
- PIP4K2A
- PIM2
- NEK7
- NEK2
- MAP3K6
- MARK2
Cross-references
Synonyms
- MK 5108
- MK5108
- VX-689
- VX 689
- MK-5108 (VX-689)
- UNII-H8J407531S
- VX689
- CHEMBL3600873
- H8J407531S
- 4-(3-chloro-2-fluorophenoxy)-1-[[6-(1,3-thiazol-2-ylamino)pyridin-2-yl]methyl]cyclohexane-1-carboxylic acid
- 4-(3-Chloranyl-2-Fluoranyl-Phenoxy)-1-[[6-(1,3-Thiazol-2-Ylamino)pyridin-2-Yl]methyl]cyclohexane-1-Carboxylic Acid
- (1r,4r)-4-(3-chloro-2-fluorophenoxy)-1-((6-(thiazol-2-ylamino)pyridin-2-yl)methyl)cyclohexane-1-carboxylic acid
- Cyclohexanecarboxylic acid,
- MK-5108/VX-689
- 4-(3-chloranyl-2-fluoranyl-phenoxy)-1-[[6-(1,3-thiazol-2-ylamino)pyridin-2-yl]methyl]cyclohexane-1-carboxylic acid
- SCHEMBL25756236
- C22H21ClFN3O3S
- SCHEMBL1501371
- NSC773262
- CCG-269362
- EBC-221038
- SCHEMBL29396687
- BRD-K53665955-001-01-4
- BDBM50175305
- orb1689348
- s2770
- DA-65507
- BRD-K53665955-001-03-0
- AC-28427
- NSC800796
- NCGC00381554-04
- NS00073651
- SCHEMBL1501407
- SCHEMBL1501374
- AKOS030257563
- MK-5108(VX-689)
- NCGC00346657-01
- GTPL8061
- AKOS030526196
Look up MK-5108 in the interactive SynDRA portal →